Pediatrix Medical Group, Inc. (MD) Q3 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call highlights strong adjusted EBITDA, effective cost management, and a positive cash flow. Despite a year-over-year revenue decline, same-unit growth and pricing improvements are strong. The company has also been actively repurchasing shares, which is generally positive for stock price. The Q&A revealed a focus on low debt and strategic acquisitions, though some responses lacked specificity. Overall, the financial health and strategic moves suggest a positive outlook for the stock price in the short term.
Key Financial Performance
Adjusted EBITDA $87 million for the third quarter, exceeding expectations due to positive outcomes in pricing, collections, and expense controls.
Consolidated Revenue Decreased by just under $54 million year-over-year, driven by portfolio restructuring activity. This was partially offset by strong same-unit growth of 8%, with same-unit pricing up about 7.5% and patient service volumes up just under 40 basis points.
Practice-level SW&B Expenses Declined year-over-year, reflecting portfolio restructuring activity. However, on a same-unit basis, there were increases in salary expense, incentive compensation, and benefits expense. Salary growth was modestly below the prior 5-quarter average of 3% to 3.5%.
G&A Expense Increased slightly year-over-year, driven by an increase in incentive compensation expense based on overall company financial results.
Other Nonoperating Income Included a net gain on investments in divested businesses of $21 million, higher interest income on cash balances, and a decrease in interest expense due to modestly lower average borrowings at slightly lower rates.
Operating Cash Flow $138 million for the third quarter, compared to $96 million in the prior year, driven by higher earnings and increases in cash flow from accounts receivable.
Share Repurchases $21 million used during the quarter for share repurchases, with a total of 1.7 million shares repurchased to date.
Acquisitions $19 million used to acquire several neonatology, MFM, and OB hospitalist practices in a single transaction.
Cash and Net Debt Ended the quarter with $340 million in cash and net debt of just over $260 million, reflecting net leverage of just under 1x using the midpoint of the updated adjusted EBITDA outlook range for 2025.
Accounts Receivable Days Sales Outstanding (AR DSO) 43.1 days as of September 30, down over 3 days from June 30 and almost 9 days year-over-year, driven by improved cash collections at existing units.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
BabySteps system: A proprietary system designed to support clinicians in caring for mothers and high-risk NICU patients. It enhances clinical decision-making, increases efficiency and accuracy in documentation, mitigates risks, and reduces cognitive burden for clinicians. It is constantly updated based on quality and research team input.
Market-leading position: Pediatrix has a significant clinical scale with over 1,300 physicians and 1,170 advanced practice providers across 322 locations in 33 states. It maintains a comprehensive clinical data warehouse with 37 million patient days and 2 million NICU admissions.
Portfolio expansion: Acquired several neonatology, MFM, and OB hospitalist practices in a single transaction, successfully integrating them on schedule.
Revenue and cash flow: Generated $138 million in operating cash flow in Q3 2025, up from $96 million in the prior year. Consolidated revenue decreased due to portfolio restructuring but was offset by strong same-unit growth of 8% and pricing increases of 7.5%.
Expense management: Practice-level SW&B expenses declined year-over-year due to portfolio restructuring. G&A expenses increased slightly due to higher incentive compensation.
Adjusted EBITDA: Achieved $87 million in adjusted EBITDA for Q3 2025, exceeding expectations. Full-year adjusted EBITDA outlook is $270 million to $290 million.
Focus areas: Restructured portfolio to concentrate on pediatric surgery, neurology, cardiac intensive care, and other specialized areas. Plans to prioritize enhanced technological support for clinicians.
Research and innovation: Active in 72 clinical research studies across 39 sites, with 1,395 peer-reviewed publications. Research is diversified across federal, industry, and international funding sources. Commitment to research drives quality, safety, and innovation.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Portfolio Restructuring: The company's consolidated revenue decreased due to portfolio restructuring activity, which resulted in a revenue reduction of just under $54 million. This restructuring could pose challenges in maintaining revenue growth and operational stability.
Salary and Compensation Costs: Increases in salary expenses, incentive compensation, and benefits expenses on a same-unit basis could pressure operating margins, especially if revenue growth does not keep pace with these rising costs.
Economic and Healthcare Industry Headwinds: The CEO acknowledged significant healthcare industry headwinds, which could impact the company's ability to sustain its current performance levels and achieve future growth.
Debt and Financial Leverage: The company has net debt of just over $260 million, which, while manageable, could become a challenge if cash flow generation weakens or interest rates rise.
Operational and Strategic Execution Risks: The company is focusing on expanding its technological capabilities and research activities, but these initiatives require significant investment and carry execution risks, including potential delays or cost overruns.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Adjusted EBITDA Outlook: The company expects a full year's adjusted EBITDA in the range of $270 million to $290 million, reflecting a wider-than-usual range due to practice bonus variability.
Future Portfolio Expansion: The company successfully added a portfolio of NICU, MFM, and OBH operations on schedule and expects to see more such additions going forward.
Technological Advancements: Plans to increase prioritization of enhanced technological support, including the proprietary BabySteps system, which supports clinical decision-making, improves efficiency, and reduces cognitive burden for clinicians.
Operational Strengthening: Despite significant healthcare headwinds, the company sees many opportunities to strengthen operations and results, working towards enabling a strong future.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
Share Buyback: The company disclosed in their Q filing that they bought back 1.2 million shares in the third quarter. To date, the total number of shares repurchased is 1.7 million.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:What are the company's updated thoughts on capital deployment, including share repurchase and acquisition opportunities?
A:The company has been aggressively buying back shares and is pleased with the results. They are exploring various opportunities both internally and externally but have nothing specific to detail at the moment. They continue to favor low debt, especially given current headwinds, and will report on opportunities as they arise.
Q:Has the restructuring of the portfolio changed the company's dynamics in the marketplace or competitive landscape?
A:The restructuring has strengthened the company by increasing focus and concentration of efforts. It has improved the environment for hospital partners and clinicians, enhanced recruiting efforts, and allowed the company to better address areas of need. The company believes this concentration has made them stronger overall.
Q:Can you break out the different components of the strong pricing in the quarter and provide thoughts on their durability?
A:Over one-third of the strong pricing came from robust RCM collections activity. Acuity contributed about 20%, contract administrative fees increased by 10%, and payer mix showed a 10% improvement. While payer mix is expected to remain stable, acuity and contract admin fees are variable. Collections are expected to stabilize in 2025 after a successful transition.
Q:Can you elaborate on the seasonality and other factors affecting the guidance range, particularly regarding volumes?
A:There is no specific impact from volumes. The company is working on several initiatives in the fourth quarter, which could create variability. This is the reason for a slightly wider guidance range.
Q:What are the company's thoughts on the enhanced subsidies on exchange plans and their impact on the business?
A:The company is hopeful that exchange credits will continue as they seem beneficial, though the exact impact on the business is unclear. They believe their financial strength and focus on hospital system needs will provide additional opportunities.
Q:Can you provide details on the recent acquisition and its integration into the business?
A:The recent acquisition was not material, so details were not disclosed. It involved a hospital system that chose the company over taking units in-house, recognizing the company's ability to reduce risk and provide quality initiatives. The company continues to focus on partnerships with hospital systems to grow and support their needs.
Q:Review of Unclear Management Responses
A:Management avoided providing specific details on acquisition opportunities, the exact impact of exchange plan subsidies, and the recent acquisition's financial details, citing variability and confidentiality. They also used general language about focusing on hospital system needs and financial strength without offering concrete examples or data.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
AR DSO
AR cash
Administrative Officer
CFO voice
Chief Administrative
Counsel Secretary
Dustin conference
Executive VP
Factors measure
General Counsel
Instructions conference
Moore today
OB practice
Officer Moore
Officer flu
Pricing RCM
Salary range
Secretary statement
assessment pediatrics
basis point
benefit expense
bonus variability
business increase
cash collection
cash share
collection acuity
collection expense
conference Chief
confluence outcome
control date
date number
date result
day Practice
decrease portfolio
expectation confluence
expense Salary
income
MD Transcript
Pediatrix Medical Group, Inc. (MD) Q1 2026 Earnings Call Transcript
Unknown5-5
The earnings call reveals mixed financial performance: revenue increased by 5%, but operating and net income decreased due to higher costs. EBITDA remained flat, while cash flow improved. The absence of strategic discussions and the risk acknowledgment in forward-looking statements indicate uncertainty. These mixed signals suggest a neutral stock price movement over the next two weeks.
Pediatrix Medical Group, Inc. (MD) Q4 2025 Earnings Call Transcript
Unknown2-19
The earnings report presents mixed signals. While the company shows operational strengths like improved cash collections and a share buyback program, it faces challenges with declining NICU volumes and increased G&A expenses. The Q&A section reveals uncertainties in M&A contributions and flat pricing assumptions, which could dampen growth expectations. Despite positive elements like technological advancements and operational strengthening, the overall sentiment remains neutral due to these offsetting factors.
Pediatrix Medical Group, Inc. (MD) Q3 2025 Earnings Call Transcript
Positive11-3
The earnings call highlights strong adjusted EBITDA, effective cost management, and a positive cash flow. Despite a year-over-year revenue decline, same-unit growth and pricing improvements are strong. The company has also been actively repurchasing shares, which is generally positive for stock price. The Q&A revealed a focus on low debt and strategic acquisitions, though some responses lacked specificity. Overall, the financial health and strategic moves suggest a positive outlook for the stock price in the short term.
Pediatrix Medical Group, Inc. (MD) Q2 2025 Earnings Call Transcript
Positive8-5
The earnings call summary and Q&A reveal a generally positive outlook, with a raised EBITDA outlook, strong NICU growth, and improved cash flow. While revenue decreased, same-unit revenue grew, and expenses were managed effectively. The Q&A section highlighted successful arbitration and stable margins, though management's vague responses on Medicaid expansion introduce some uncertainty. Overall, the raised guidance, strong financial performance, and strategic focus on partnerships suggest a positive stock price movement, likely within the 2% to 8% range.
MD Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
